Posted by Michael Wonder on 21 Apr 2026
BBOT granted US FDA fast track designation for BBO-11818 for the treatment of adult patients with advanced KRAS mutant pancreatic ductal adenocarcinoma
20 April 2026 - BridgeBio Oncology Therapeutics today announced that the US FDA has granted fast track designation to BBO-11818 for the treatment of adult patients with advanced KRAS mutant pancreatic ductal adenocarcinoma.
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V.
